These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

77 related items for PubMed ID: 7446747

  • 1. Endogenous anticoagulation during extracorporeal perfusion: generation of a heparinlike inhibitor.
    Murphy TL, Walker FJ, Taylor FB, Beller-Todd B, Archer LT, Sofer SS, Hinshaw LB.
    Am J Physiol; 1980 Dec; 239(6):H742-50. PubMed ID: 7446747
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A protamine filter for extracorporeal heparin removal. Development, testing, blood compatibility evaluation, and future direction.
    Byun Y, Yun JH, Han IS, Fu Y, Shanberge JN, Yang VC.
    ASAIO J; 1995 Dec; 41(3):M301-5. PubMed ID: 8573812
    [Abstract] [Full Text] [Related]

  • 5. The monitoring of heparin activity during extracorporeal circulation.
    Gomperts ED, Bethlehem B, Hockley J.
    S Afr Med J; 1977 Jun 25; 51(26):973-6. PubMed ID: 888033
    [Abstract] [Full Text] [Related]

  • 6. Role of heparin and heparinlike molecules in thrombosis and atherosclerosis.
    Rosenberg RD.
    Fed Proc; 1985 Feb 25; 44(2):404-9. PubMed ID: 3155697
    [Abstract] [Full Text] [Related]

  • 7. Rate of protamine administration: its effect on heparin reversal and antithrombin recovery after coronary artery surgery.
    Zaidan JR, Johnson S, Brynes R, Monroe S, Guffin AV.
    Anesth Analg; 1986 Apr 25; 65(4):377-80. PubMed ID: 3954111
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The use of immobilized protamine in removing heparin and preventing protamine-induced complications during extracorporeal blood circulation.
    Yang VC, Port FK, Kim JS, Teng CL, Till GO, Wakefield TW.
    Anesthesiology; 1991 Aug 25; 75(2):288-97. PubMed ID: 1859016
    [Abstract] [Full Text] [Related]

  • 11. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
    Wolzt M, Weltermann A, Nieszpaur-Los M, Schneider B, Fassolt A, Lechner K, Eichler HG, Kyrle PA.
    Thromb Haemost; 1995 Mar 25; 73(3):439-43. PubMed ID: 7667826
    [Abstract] [Full Text] [Related]

  • 12. In vivo attempt to consume antithrombin III by i.v. injection of a thrombin-heparin mixture.
    Soulier JP, Gozin D, Lerable J.
    Thromb Res; 1984 May 01; 34(3):255-62. PubMed ID: 6729779
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Characterization of a new potent heparin. 2nd communication: Chemical analysis of the carbohydrate content and determination of the biological activity of a new potent heparin preparation in vitro, using protamine neutralization and amidolytic methods for factor Xa and thrombin.
    Bhargava AS, Heinick J, Günzel P.
    Arzneimittelforschung; 1980 May 01; 30(7):1071-4. PubMed ID: 7191289
    [Abstract] [Full Text] [Related]

  • 15. Interrelationship of protamine and platelet factor 4 in the neutralization of heparin.
    Shanberge JN, Quattrociocchi-Longe TM, Martens MH.
    Thromb Res; 1987 Apr 01; 46(1):89-100. PubMed ID: 3590116
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of bypass surgery on coagulation-sensitive clotting factors.
    Woods JE, Kirklin JW, Owen CA, Thompson JH, Taswell HF.
    Mayo Clin Proc; 1967 Nov 01; 42(11):724-35. PubMed ID: 6053800
    [No Abstract] [Full Text] [Related]

  • 18. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation.
    Despotis GJ, Joist JH, Hogue CW, Alsoufiev A, Kater K, Goodnough LT, Santoro SA, Spitznagel E, Rosenblum M, Lappas DG.
    J Thorac Cardiovasc Surg; 1995 Jul 01; 110(1):46-54. PubMed ID: 7609568
    [Abstract] [Full Text] [Related]

  • 19. Prolonged bleeding time induced by anticoagulant glycosaminoglycans in dogs is associated with the inhibition of thrombin-induced platelet aggregation.
    Kitazato K, Kitazato KT, Sasaki E, Minamiguchi K, Nagase H.
    Thromb Res; 2003 Jul 01; 112(1-2):83-91. PubMed ID: 15013278
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.